Rapid on-line profiling of estrogen receptor binding metabolites of tamoxifen

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3287-3292

  Kool, Jeroen ^a   Ramautar, Rawi ^a   Van Liempd, Sebastiaan M ^a   Beckman, Joran ^a   De Kanter, Frans J J ^a   Meerman, John H N ^a   Schenk, Tim ^b   Irth, Hubertus ^b   Commandeur, Jan N M ^a   Vermeulen, Nico P E ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Kiadis BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; DRUG METABOLITE; ESTROGEN RECEPTOR ALPHA; NOR 4 HYDROXYTAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HORMONE RECEPTOR INTERACTION; LIVER MICROSOME; MASS SPECTROMETRY; METHODOLOGY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SWINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; LIGANDS; MICROSOMES, LIVER; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SWINE; TAMOXIFEN;

EID: 33744827984     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0507936     Document Type: Article

References (29)

1. Fura, A.; Shu, Y. Z.; Zhu, M.; Hanson, R. L.; Roongta, V.; Humphreys, W. G. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J. Med. Chem. 2004, 47 (18), 4339-51.
2. Oosterkamp, A. J.; Villaverde Herraiz, M. T.; Irth, H.; Tjaden, U. R.; van der Greef, J. Reversed-phase liquid chromatography coupled on-line to receptor affinity detection based on the human estrogen receptor. Anal. Chem. 1996, 68 (7), 1201-6.
3. Rodbard, D. Mathematics of hormone-receptor interaction. I. Basic principles. Adv. Exp. Med. Biol. 1973, 36, 289-326.
4. Ziegler, L. D.; Buzdar, A. U. Current status of adjuvant therapy of early breast cancer. Am. J. Clin. Oncol 1991, 14 (2), 101-10.
5. Mani, C.; Gelboin, H. V.; Park, S. S.; Pearce, R.; Parkinson, A.; Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 1993, 21 (4), 645-56.
6. Mani, C.; Hodgson, E.; Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos. 1993, 21 (4), 657-61.
7. Desta, Z.; Ward, B. A.; Soukhova, N. V.; Flockhart, D. A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 2004, 310 (3), 1062-75.
8. Loser, R.; Seibel, K.; Eppenberger, U. No loss of estrogenic or anti-estrogenic activity after demethylation of droloxifene (3-OH-tamoxifen). Int. J. Cancer 1985, 36 (6), 701-3.
9. Bates, D. J.; Foster, A. B.; Griggs, L. J.; Jarman, M.; Leclercq, G.; Devleeshouwer, N. Metabolism of tamoxifen by isolated rat hepatocytes: anti-estrogenic activity of tamoxifen N-oxide. Biochem. Pharmacol. 1982, 31 (17), 2823-7.
10. Crewe, H. K.; Motley, L. M.; Wunsch, R. M.; Lennard, M. S.; Gillam, E. M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 2002, 30 (8), 869-74.
11. Coller, J. K.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U. M.; Eichelbaum, M.; Murdter, T. E. Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br. J. Clin. Pharmacol. 2004, 57 (1), 105-11.
12. Parr, I. B.; McCague, R.; Leclercq, G.; Stoessel, S. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of 1-[4-(2-hydroxyethoxy) phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene and the dependence of N-oxidation on oxygen availability. Biochem. Pharmacol. 1987, 36 (9), 1513-9.
13. Lim, C. K.; Yuan, Z. X.; Jones, R. M.; White, I. N.; Smith, L. L. Identification and mechanism of formation of potentially genotoxic metabolites of tamoxifen: study by LC-MS/MS. J. Pharm. Biomed. Anal. 1997, 15 (9-10), 1335-42.
14. Gamboa da Costa, G.; Marques, M. M.; Freeman, J. P.; Beland, F. A. Synthesis and investigation of alpha-hydroxy-N,N-didesmethyl-tamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen. Chem. Res. Toxicol. 2003, 16 (9), 1090-8.
15. Kemp, J. V.; Adam, H. K.; Wakeling, A. E.; Slater, R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem. Pharmacol. 1983, 32 (13), 2045-52.
16. Johnson, M. D.; Zuo, H.; Lee, K. H.; Trebley, J. P.; Rae, J. M.; Weatherman, R. V.; Desta, Z.; Flockhart, D. A.; Skaar, T. C. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 2004, 85 (2), 151-9.
17. Poon, G. K.; Walter, B.; Lonning, P. E.; Horton, M. N.; McCague, R. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 1995, 23 (3), 377-82.
18. Dehal, S. S.; Kupfer, D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos. 1999, 27 (6), 681-8.
19. McCague, R.; Seago, A. Aspects of metabolism of tamoxifen by rat liver microsomes. Identification of a new metabolite: E-1-[4-(2-dimethylaminoethoxy)- phenyl]-1,2-diphenyl-1-buten-3-ol N-oxide. Biochem. Pharmacol. 1986, 35 (5), 827-34.
20. Lim, H. K.; Stellingweif, S.; Sisenwine, S.; Chan, K. W. Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding. J. Chromatogr. A 1999, 831 (2), 227-41.
21. Sun, Y.; Gu, C.; Liu, X.; Liang, W.; Yao, P.; Bolton, J. L.; van Breemen, R. B. Ultrafiltration tandem mass spectrometry of estrogens for characterization of structure and affinity for human estrogen receptors. J. Am. Soc. Mass Spectrom. 2005, 16 (2), 271 -9.
22. Stearns, V.; Johnson, M. D.; Rae, J. M.; Morocho, A.; Novielli, A.; Bhargava, P.; Hayes, D. F.; Desta, Z.; Flockhart, D. A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003, 95 (23), 1758-64.
23. Jordan, V. C.; Collins, M. M.; Rowsby, L.; Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 1977, 75 (2), 305-16.
24. Lewis, J. S.; Jordan, V. C. Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 2005.
25. Rooney, P. H.; Telfer, C.; McFadyen, M. C.; Melvin, W. T.; Murray, G. I. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr. Cancer Drug Targets 2004, 4 (3), 257-65.
26. Rooseboom, M.; Commandeur, J. N.; Floor, G. C.; Rettie, A. E.; Vermeulen, N. P. Selenoxidation by flavin-containing monooxygenases as a novel pathway for beta-elimination of selenocysteine Se-conjugates. Chem. Res. Toxicol. 2001, 14 (1), 127-34.
27. Eiler, S.; Gangloff, M.; Duclaud, S.; Moras, D.; Ruff, M. Overexpression, purification, and crystal structure of native ER alpha LBD. Protein Expr. Purif. 2001, 22 (2), 165-73.
28. van Lipzig, M. M.; ter Laak, A. M.; Jongejan, A.; Vermeulen, N. P.; Wamelink, M.; Geerke, D.; Meerman, J. H. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. J. Med. Chem. 2004, 47 (4), 1018-30.
29. Schobel, U.; Frenay, M.; van Elswijk, D. A.; McAndrews, J. M.; Long, K. R.; Olson, L. M.; Bobzin, S. C.; Irth, H. High resolution screening of plant natural product extracts for estrogen receptor alpha and beta binding activity using an online HPLC-MS biochemical detection system. J. Biomol. Screen 2001, 6 (5), 291-303.